Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.30 |
| ▸ | CPN1 | P15169 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18497422 | 0.86 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1RAB9AGPR119 | |
| SCHEMBL18497596 | 0.82 | GPR119 (0.47) | GPR119 | |
| SCHEMBL3533847 | 0.80 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1POLBGPR119 | |
| SCHEMBL458216 | 0.77 | GPR119 (0.38) | ALDH1A1LMNAGPR119 | |
| SCHEMBL4438764 | 0.75 | GPR119 (0.44) | ALDH1A1LMNARAB9AGPR119 | |
| SCHEMBL18497511 | 0.74 | DPP4 (0.33) | ALDH1A1 | |
| SCHEMBL12503814 | 0.74 | RBP4 (0.36) | ALDH1A1L3MBTL1LMNAPOLBRAB9A | |
| SCHEMBL3717160 | 0.74 | RBP4 (0.36) | ALDH1A1L3MBTL1LMNAPOLBRAB9A | |
| SCHEMBL18641574 | 0.74 | RBP4 (0.36) | ALDH1A1L3MBTL1LMNAPOLBRAB9A | |
| SCHEMBL27793398 | 0.72 | ALDH1A1 (0.40) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9682965-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017027684-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ALDH1A1 450/4885L3MBTL1 4176/4885LMNA 3216/4885 |
| US-20170066749-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ALDH1A1 450/4885L3MBTL1 4176/4885LMNA 3216/4885 |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ALDH1A1 450/4885L3MBTL1 4176/4885LMNA 3216/4885 |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | ALDH1A1 450/4885L3MBTL1 4176/4885LMNA 3216/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | ALDH1A1 450/4885L3MBTL1 4176/4885LMNA 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.